Halberd (Halberd) Insider Ownership : 75.60 % (As of Jun. 17, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Halberd's insider ownership is 75.60%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Halberd's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Halberd's Float Percentage Of Total Shares Outstanding is 0.00%.

Halberd Insider Ownership Historical Data

The historical data trend for Halberd's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Insider Ownership Chart

Halberd Historical Data

The historical data trend for Halberd can be seen below:

	2018-02-28	2018-03-31	2018-04-30	2018-05-31	2018-06-30	2018-07-31	2018-08-31	2018-09-30	2018-10-31	2018-11-30
Insider Ownership	75.60	75.60	75.60	75.60	75.60	75.60	75.60	75.60	75.60	75.60

Halberd Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236